Navigation Links
Reportlinker Adds Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Date:8/31/2010

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

http://www.reportlinker.com/p0286297/Women's-Health-Therapeutics-Analysis-and-Market-Forecasts-to-2016---High-Unmet-Need-will-Drive-the-Uptake-of-Novel-Drugs-in-the-Menopause-and-Osteoporosis-Markets.html

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

SummaryGBI Research's report, "Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis", provides in-depth analysis of unmet needs, drivers and barriers that impact the global women's health market. The report analyzes the markets for women's health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

ScopeThe Scope
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
2. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
3. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
4. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
5. Reportlinker Adds Advances in Biopharmaceutical Technology in China
6. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
7. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
8. Reportlinker Adds Stem Cells Market And Applications. 2009-2015
9. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
10. Reportlinker Adds Global Nucleic Acid Testing Industry
11. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
(Date:7/28/2015)... NESS ZIONA, Israel ... CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company ... repair products, today announced that Shomrat Shurtz has ... September 20, 2015.      (Photo: ... brings over 25 years of experience in marketing, ...
(Date:7/28/2015)... , July 28, 2015  Faced with increasing ... are palliative rather than symptomatic, the global healthcare ... existing therapies capable of curing or significantly changing ... starting to look towards regenerative medicine as a ... new paradigm in human health with the potential ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... LLC announced today that the first patient has ... support a new fixed-dose combination (FDC) therapy for ... known as 572-Trii, will combine the investigational integrase ... reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... could jumpstart the promising field of cell therapy, in which ... of diseases and tissue defects, researchers at Brigham and Women,s ... the key challenges associated with the procedure: control of the ... reported in the journal Biomaterials on January 26, ...
... has become a standard tool in the search for ... disaster, but until now there has been very little ... policy challenges associated with this new use of genetic ... National Institutes of Health (NIH) has awarded Carnegie ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 2CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 4
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... measure organic contaminants in human body fluids, the National ... four new Standard Reference Materials (SRMs) available for purchase. ... and Prevention (CDC), the human milk and serum SRMs ... pesticides, commonly found in the U.S. population. Scientists at ...
... Netherlands: For the first time, researchers have been able ... of IVF treatment in blood. Dr. Cathy Allen, from the ... the European Society of Human Reproduction and Embryology today (Wednesday ... works for some patients but not for others. Previous ...
Cached Biology News:Genetically engineered mice yield clues to 'knocking out' cancer 2NIST issues human milk and blood serum SRMs for contaminant measurements 2Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3